表紙
市場調查報告書

色素性視網膜炎(視網膜炎):開發平台分析

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 200486
出版日期 內容資訊 英文 234 Pages
訂單完成後即時交付
價格
Back to Top
色素性視網膜炎(視網膜炎):開發平台分析 Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 234 Pages
簡介

色素性視網膜炎(RP),是作用於視網膜的一連串遺傳性眼科疾病的通稱。RP會對光受體細胞(視網膜內部偵測光的細胞)造成破壞,由於光受體細胞具有捕捉、處理光線使眼睛有看見東西的效果,光受體細胞遭到破壞、壞死將導致視力逐漸喪失。各種RP的共通特徵更是視桿細胞(偵測微光的視網膜細胞)和錐體細胞(偵測光、色彩的視網膜細胞)逐漸喪失,不過最初階段大部分是喪失視桿細胞。這種形態的RP(也叫桿錐細胞退化),會先從夜盲症開始。所謂夜盲症,是類似於我們從明亮的戶外進入黑暗的電影院中所感到的感覺那樣的症狀。

本報告提供全球各國的色素性視網膜炎(視網膜炎)所用的開發中產品之開發情形相關分析,提供您開發中產品的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要(產品概要,功能機制,研究開發(R&D)的發展情形),最新的產業趨勢等調查。

簡介

  • 分析範圍

色素性視網膜炎(視網膜炎)概要

治療藥的開發

  • 色素性視網膜炎(視網膜炎)開發中產品:概要
  • 色素性視網膜炎(視網膜炎)開發中產品:比較分析

各企業正在開發的色素性視網膜炎(視網膜炎)治療藥

大學/研究機關研究中的色素性視網膜炎(視網膜炎)治療藥

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品

色素性視網膜炎(視網膜炎)治療藥:開發中的產品一覽(各企業)

色素性視網膜炎(視網膜炎)治療藥:研究中的產品一覽(各大學/研究機關)

色素性視網膜炎(視網膜炎)開發治療藥的企業

  • Acucela Inc.
  • Amarantus Bioscience Holdings, Inc.
  • Amgen Inc.
  • Applied Genetic Technologies Corporation
  • Asklepios BioPharmaceutical, Inc.
  • Astellas Pharma Inc.
  • Caladrius Biosciences, Inc.
  • Dompe Farmaceutici S.p.A.
  • Genable Technologies Limited
  • Genethon
  • GenSight Biologics S.A.
  • Grupo Ferrer Internacional, S.A.
  • ID Pharma Co., Ltd.
  • InFlectis BioScience
  • International Stem Cell Corporation
  • Ionis Pharmaceuticals, Inc.
  • M's Science Corporation
  • Mimetogen Pharmaceuticals Inc.
  • Nanovector s.r.l.
  • Orphagen Pharmaceuticals, Inc.
  • QLT Inc.
  • RegenxBio Inc.
  • ReNeuron Group Plc
  • SanBio, Inc.
  • Sanofi
  • Shire Plc
  • Spark Therapeutics, Inc.
  • Staidson (Beijing) Biopharmaceuticals Co.,td.
  • Sucampo Pharmaceuticals, Inc.
  • Sun Pharma Advanced Research Company Ltd

肝臟病:治療藥的評估

  • 單劑治療藥的情況
  • 標的別
  • 各行動機制
  • 各投藥法
  • 各分子類型

藥物簡介

肝臟病治療藥:最新的開發平台趨勢

肝臟病治療藥:開發暫停的產品

肝臟病治療藥:開發中止的產品

肝臟病相關產品的開發的里程碑

  • 值得注意的最新趨勢·新聞稿

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11790IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019, provides an overview of the Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline landscape.

Retinitis Pigmentosa (RP) refers to a group of diseases which cause a slow but progressive vision loss. Retinitis pigmentosa is caused by a genetic defect. Symptoms include night blindness and loss of peripheral vision. The predisposing factors include autosomal dominant inheritance, autosomal recessive inheritance and x-linked inheritance.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Retinitis Pigmentosa (Retinitis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 15, 3, 1, 35 and 12 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 11 molecules, respectively.

Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Retinitis Pigmentosa (Retinitis) (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Retinitis Pigmentosa (Retinitis) (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Retinitis Pigmentosa (Retinitis) (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Retinitis Pigmentosa (Retinitis) - Overview
    • Retinitis Pigmentosa (Retinitis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
    • 4D Molecular Therapeutics Inc
    • Acucela Inc
    • Advanced Medical Projects
    • Allegro Ophthalmics LLC
    • Allergan Plc
    • Alpine Biotherapeutics Corp
    • Amarantus Bioscience Holdings Inc
    • Amgen Inc
    • Ankar Pharma SL
    • Applied Genetic Technologies Corp
    • Biogen Inc
    • Brighton Biotech Inc
    • Casebia Therapeutics
    • Dompe Farmaceutici SpA
    • Editas Medicine Inc
    • Endogena Therapeutics Inc
    • EyePoint Pharmaceuticals Inc
    • Eyestem Research Pvt Ltd
    • Eyevensys SAS
    • GenSight Biologics SA
    • Grupo Ferrer Internacional SA
    • Horama SA
    • ID Pharma Co Ltd
    • IVERIC bio Inc
    • jCyte Inc
    • Kyoto Drug Discovery & Development Co Ltd
    • Lineage Cell Therapeutics Inc
    • MeiraGTx Holdings Plc
    • MimeTech Srl
    • Miragen Therapeutics Inc
    • Mireca Medicines GmbH
    • NanoScope Technologies LLC
    • Nanovector srl
    • Novartis AG
    • Ocugen Inc
    • OliX Pharmaceuticals Inc
    • ONL Therapeutics Inc
    • OptiKira LLC
    • Oxford BioMedica Plc
    • Phylogica Ltd
    • Precision Biosciences Inc
    • Profarma
    • ProQR Therapeutics NV
    • Recursion Pharmaceuticals Inc
    • ReNeuron Group Plc
    • Retinagenix LLC
    • SanBio Inc
    • SparingVision SAS
    • Staidson BioPharma Inc
    • Sumitomo Dainippon Pharma Co Ltd
    • Wave Life Sciences Ltd
  • Retinitis Pigmentosa (Retinitis) - Drug Profiles
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products
  • Retinitis Pigmentosa (Retinitis) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Advanced Medical Projects, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Allegro Ophthalmics LLC, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Pipeline by Allergan Plc, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2019
  • Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2019 (Contd..1), H2 2019
  • Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Routes of Administration, H2 2019
  • Number of Products by Stage and Routes of Administration, H2 2019
  • Number of Products by Molecule Types, H2 2019
  • Number of Products by Stage and Molecule Types, H2 2019
Back to Top